ObjectiveTo explore the efficacy and recurrence of febuxostat combined with potassium citrate extended-release tablets in the treatment of gouty nephrolithiasis. MethodsA total of 120 patients with gouty nephrolithiasis hospitalized in our hospital from December 2018 to December 2019 were selected, and they were divided into simple group and combined group by the envelope method, with 60 cases in each group. Patients in the simple group were treated with febuxostat, whereas patients in the combined group were treated with febuxostat combined with potassium citrate extended-release tablets, for a treatment course of 14 days. The clinical therapeutic effects, serum soluble intercellular adhesion molecule 1 (sICAM-1) and blood uric acid levels were compared between the two groups. For a six-month follow-up, the recurrence rates of the two groups were compared. ResultsAfter 14 days of treatment, the total effective rate (70.0%) of the simple group was significantly lower than that of the combined group (86.7%), and the difference was statistically significant (P＜0.05). Before treatment, there were no statistically significant differences in serum uric acid and blood sICAM-1 levels between the two groups (P＞0.05). After 14 days of treatment, the blood uric acid and sICAM-1 levels of the two groups significantly decrease, and the levels of the combined group were significantly lower than those of the simple group (P＜0.05). After 6 months of follow-up, 8 patients in the simple group and 3 patients in the combined group relapsed, but there was no statistically significant difference in the recurrence rate between the two groups (P＞0.05). ConclusionFebuxostat combined with potassium citrate extended-release tablets has a prominent clinical efficacy in the treatment of patients with gouty nephrolithiasis, which can significantly decrease the level of blood uric acid and inflammatory response level in patients, and decrease the recurrence rate of patients, and thus it is worthy of promotion and application.

无